Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to investigate the effect of bariatric surgery on cardiac function assessed by echocardiography in patients with hypertension.
Obesity is the most common chronic metabolic disease worldwide, causing the increasing burden of cardiovascular risk factors such as hypertension, and affecting cardiac structure and function in the long term. Nowadays, bariatric surgery is regarded as the most effective approach for weight loss, and the only approach for reducing obesity-related cardiovascular events. However, the effect of different bariatric surgeries such as laparoscopic sleeve gastrectomy (LSG) or Roux-en-Y gastric bypass (RYGB) on cardiac function in patients with hypertension is still unclear. Therefore, the aim of this study was to evaluate the benefit of different bariatric surgeries on cardiac structure and function echocardiography in patients with hypertension.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| LSG group | Laparoscopic sleeve gastrectomy (LSG) performed as a treatment for obesity |
| |
| RYGB group | Laparoscopic Roux-en-Y gastric bypass performed as a treatment for obesity |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| LSG | Procedure | Laparoscopic sleeve gastrectomy (LSG) together with medical treatment aiming the control of cardiovascular risks including hypertension, diabetes mellitus or dyslipidemia. |
| Measure | Description | Time Frame |
|---|---|---|
| Changes on left ventricular ejection fraction (LVEF) | Changes on LVEF in % assessed with the use of transthoracic echocardiography (TTE). | 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Changes on left ventricular ejection fraction (LVEF) | Changes on LVEF in % assessed with the use of TTE. | 24 months |
| Changes on left ventricular end-diastolic diameter (LVEDD) | Changes on LVEDD in mm assessed with the use of TTE. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Obese patients with hypertension
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Rongchong Huang, M.D. | Contact | +86-13811039417 | rchuang@ccmu.edu.cn |
| Name | Affiliation | Role |
|---|---|---|
| Rongchong Huang, M.D. | Beijing Friendship Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Beijing Friendship Hospital, Capital Medical University | Recruiting | Beijing | Beijing Municipality | 100050 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006973 | Hypertension |
| ID | Term |
|---|---|
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| RYGB | Procedure | Roux-en-Y gastric bypass (LRYGB) together with medical treatment aiming the control of cardiovascular risks including hypertension, diabetes mellitus or dyslipidemia. |
|
| 12 months |
| Changes on left ventricular end-diastolic diameter (LVEDD) | Changes on LVEDD in mm assessed with the use of TTE. | 24 months |
| Major adverse cardiac events | including all-cause mortality, cardiac death, acute myocardial infarction, stroke, heart failure, ventricular tachycardia or ventricular fibrillation requiring shock delivery. | 12 months |
| Major adverse cardiac events | including all-cause mortality, cardiac death, acute myocardial infarction, stroke, heart failure, ventricular tachycardia or ventricular fibrillation requiring shock delivery. | 24 months |
| Changes on number of antihypertensive drugs | Changes on of the total number of antihypertensive medications while maintaining office systolic and diastolic blood pressure <140 mm Hg and 90 mm Hg, respectively. | 12 months |
| Changes on number of antihypertensive drugs | Changes on of the total number of antihypertensive medications while maintaining office systolic and diastolic blood pressure <140 mm Hg and 90 mm Hg, respectively. | 24 months |
| Changes on blood pressure | Changes on systolic and blood pressure assessed with the use of 24-hour ABPM. | 12 months |
| Changes on blood pressure | Changes on systolic and blood pressure assessed with the use of 24-hour ABPM. | 24 months |